MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Merck & Co., Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$143.63−2.32 (-1.59%)
Close on Oct 19, 2026
- Market cap
- $354.77B
- P/E (TTM)
- 114.9
- Dividend yield
- 2.28%
Share price
+$58.84 (+69.39%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
Merck & Co., Inc. grew revenue 4.6% to $66.57B over the twelve months to Jun 30, 2026. Free cash flow was $16.06B, up 9.1% from a year earlier.
Revenue
$66.57B
+4.6% vs. a year earlier
Free cash flow
$16.06B
+9.1% vs. a year earlier
EPS, diluted
$1.25
-80.7% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $354.77B
- P/E ratio
- 114.9
- Price to sales
- 5.33
- Price to book
- 8.46
- Dividend yield
- 2.28%
- Free cash flow yield
- 4.53%
Fundamentals
- Revenue
- $66.57B
- Net income
- $3.17B
- EPS, diluted
- $1.25
- Free cash flow
- $16.06B
- Book value per share
- $16.98
- Diluted shares
- 2.47B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$66.57B+4.6% YoY
Gross profit
$48.57B-0.3% YoY
Net income
$3.17B-80.7% YoY
EPS, diluted
$1.25-80.7% YoY
Free cash flow
$16.06B+9.1% YoY
Reported periodTrailing twelve months